Signet Announces the Availability of Monoclonal Prion Antibody 6D11
Complete the form below to unlock access to ALL audio articles.
Signet Laboratories, Inc. has announced the availability of Monoclonal Prion Antibody 6D11.
Prion diseases, or Transmissible Spongiform Encephalopathies (TSE), are degenerative diseases of the nervous system caused by transmissible particles that contain a pathogenic isoform of the prion protein, a normal constituent of cell membranes.
Although cross- species transmission of prion diseases seems to be limited by a “species barrier,” the occurrence of bovine spongiform encephalopathy (BSE) and its transmission to humans indicate that animal prion diseases can pose a significant public health risk.
“The development of highly sensitive assays for ante mortem detection of misfolded prions is a top priority for minimizing the spread of the disease,” stated Joe Bertelsen, Neuroscience Product Manager for Signet Laboratories.
“Signet's new 6D11 antibody, in addition to Signet's existing prion antibody panel, gives researchers a powerful tool for developing such screening systems.”
